BBIO · ISSUER CIK 1743881
BridgeBio Pharma, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 BridgeBio Pharma, Inc. insiders reported $0.00 of open-market purchases and $4.6M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$4.6MInsider selling
−$4.6MNet open-market
Sep 21, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 202618:21 | Sep 17, 2026 | BBIO | Chief Executive Officer, Director | S · Sell10b5-1 | $69.08 | −10,000 | 495,686 | -2% | −$691K | ||
| Aug 20, 202616:31 | Aug 19, 2026from Aug 18, 2026 | BBIO | Chief Executive Officer, Director | S · Sell10b5-1 | $82.86 | −44,980 | 243,327 | -16% | −$3.7M | ||
| Aug 18, 202618:02 | Aug 16, 2026 | BBIO | President and CFO | F · Tax | $79.86 | −22,781 | 336,529 | -6% | $1.8M | ||
| Aug 18, 202618:02 | Aug 16, 2026 | BBIO | Chief Executive Officer, Director | M · Exercise | — | +71,217 | 314,544 | +29% | — | ||
| Aug 18, 202618:02 | Aug 16, 2026 | BBIO | Chief Executive Officer, Director | F · Tax | $79.86 | −36,237 | 278,307 | -12% | $2.9M | ||
| Aug 18, 202618:02 | Aug 16, 2026 | BBIO | Chief Accounting Officer | F · Tax | $79.86 | −4,714 | 122,687 | -4% | $376K | ||
| Aug 3, 202616:20 | Jul 30, 2026 | BBIO | Chief Accounting Officer | S · Sell10b5-1 | $80.06 | −2,000 | 127,401 | -2% | −$160K |